Key Events This Week
10 Aug: Bullish momentum observed with technical upgrades
14 Aug: Sharp quarterly decline reported
14 Aug: Stock hits lower circuit amid heavy selling
14 Aug: Technical momentum shifts to mildly bullish with mixed indicators

Kilitch Drugs Reports Sharp Quarterly Decline Amid Shifting Financial Trends
2026-08-14 12:00:08Kilitch Drugs (India) Ltd has experienced a marked deterioration in its recent quarterly financial performance, with key metrics such as net sales and profit after tax (PAT) showing significant declines compared to historical averages. This shift has prompted a downgrade in the company’s mojo grade to Sell, reflecting growing concerns over its operational and financial health amid a challenging market environment.
Read full news article
Kilitch Drugs (India) Ltd is Rated Hold
2026-08-14 10:10:03Kilitch Drugs (India) Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 08 June 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 14 August 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Below All Moving Averages and Now at Lower Circuit: Kilitch Drugs (India) Ltd Loses 5.0% in a Single Session
2026-08-14 10:00:07At Rs 181.66, sellers were still queuing — but there were no buyers willing to take the other side. Kilitch Drugs (India) Ltd locked at its lower circuit of 5.0% on 14 Aug 2026, with unfilled sell orders and a frozen price, reflecting persistent selling pressure in a micro-cap stock.
Read full news article
Kilitch Drugs (India) Ltd Technical Momentum Shifts Amid Mixed Indicators
2026-08-14 08:00:42Kilitch Drugs (India) Ltd has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent downgrade in its market sentiment, the stock’s price action and key technical indicators suggest a cautiously optimistic outlook for investors navigating the Pharmaceuticals & Biotechnology sector.
Read full news article
Kilitch Drugs (India) Ltd Shows Bullish Momentum Amid Technical Upgrades
2026-08-10 08:00:37Kilitch Drugs (India) Ltd has demonstrated a notable shift in price momentum and technical indicators, signalling a transition from a mildly bullish to a more confident bullish trend. This development is underscored by improvements in key metrics such as the MACD, moving averages, and Bollinger Bands, while some oscillators present mixed signals. Investors and analysts are closely monitoring these changes as the micro-cap pharmaceutical player attempts to consolidate gains amid broader market volatility.
Read full news article
Kilitch Drugs (India) Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-08-07 08:00:43Kilitch Drugs (India) Ltd has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish trend as of early August 2026. Despite a recent decline in share price, key technical indicators such as MACD and moving averages continue to signal underlying strength, while others like RSI suggest caution. This nuanced technical landscape offers investors a complex picture of the pharmaceutical micro-cap’s near-term prospects.
Read full news article
Kilitch Drugs (India) Ltd Technical Momentum Shifts Signal Bullish Outlook
2026-08-06 08:00:44Kilitch Drugs (India) Ltd has demonstrated a notable shift in price momentum, supported by a series of bullish technical indicators and an upgrade in its Mojo Grade from Sell to Hold. The pharmaceutical micro-cap stock has outperformed the Sensex year-to-date, reflecting improving investor sentiment and technical strength.
Read full news article
Kilitch Drugs (India) Ltd is Rated Hold
2026-08-03 10:10:04Kilitch Drugs (India) Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article





